Aditx Therapeutics, Inc. (Aditxt™) is a pre-clinical stage, life sciences company with a mission to prolong life and enhance life quality of transplanted patients. Aditxt™’s current portfolio includes an exclusive worldwide license for commercializing Apoptotic DNA Immunotherapy™ (ADi™), which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues.